Inactive Instrument

Insiders NeuroVive Pharmaceutical AB Swiss Exchange

Equities

NVP

SE0002575340

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

Amendment of the Nomination Committee's proposal for Abliva’s Annual General Meeting in 2023	04/05/23	AQ
Abliva AB Announces Resignation of Edwin Moses as Director	04/05/23	CI
Abliva AB Elects Edwin Moses as New Board Member	08/03/23	CI
Abliva Nomination Committee to propose Edwin Moses as a new Board member and incoming Chair of the Board of Directors at upcoming General Meetings	13/02/23	AQ
Abliva Announces CEO Changes, with Effect from February 3rd	20/01/21	CI
Abliva AB Announces Resignation of Magnus Persson From Board of Directors	08/10/20	CI
NeuroVive Pharmaceutical AB will Change its Name to Abliva AB	27/05/20	CI
NeuroVive Pharmaceutical AB Elects Roger Franklin as New Board Member; Approves Amendment to the Articles of Association	20/05/20	CI
NeuroVive Pharmaceutical : Nomination Committee amends its proposal to the 2020 Annual General Meeting	29/04/20	AQ
NeuroVive Pharmaceutical : Nomination Committee amends its proposal to the 2020 Annual General Meeting	28/04/20	AQ
NeuroVive Pharmaceutical AB Elects Magnus Persson as New Board Member	25/04/19	CI
NeuroVive Pharmaceutical AB Appoints Denise Goode as New Board Member	27/04/18	CI
NeuroVive Pharmaceutical AB Announces Board Changes	07/11/17	CI
NeuroVive Pharmaceutical AB Appoints Daniel Schale as Director of Communications	04/10/17	CI
NeuroVive Pharmaceutical AB Appoints Mark Farmery as Vice President Business Development	01/09/17	CI
Neurovive Pharmaceutical AB Appoints Philippe Gallay and Massimo Pinzani as Scientific Advisors	22/02/17	CI
NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee	26/10/16	PU
NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee	26/10/16	BU
NeuroVive Pharmaceutical AB's Chief Operating Officer Jan Nilsson Leaves the Company	24/08/16	CI
NeuroVive Pharmaceutical AB Appoints Cecilia Hofvander as Investor Relations and Communications Director, Effective June 1, 2016	11/04/16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders NeuroVive Pharmaceutical AB Swiss Exchange

Equities

NVP

SE0002575340

Insiders

Filters